Fairvalue-Calculator Fairvalue-Calculator

JS Link, Inc (127120) Fair Value & Analysis

Healthcare · KR · Market cap 1.1T KRW

Price35,150 KRW
Fair Value8,947 KRW
Upside-74.5%
Quality95/100
Evidence: Low Range 6,711 KRW – 11,184 KRW

Analysis

JS Link, Inc (127120) currently trades at 35,150 KRW, while our model-based Fair Value estimate is 8,947 KRW — implying the stock looks roughly 74.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In addition, it provides rare earth and permanent magnets. The company was formerly known as DNA Link, Inc. and changed its name to JS Link, Inc. in April 2025. JS Link, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Alnylam Pharmaceuticals, Inc (ALNY) -63% Samsung Biologics Co (207940) +1%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.